Hyperbaric oxygen therapy (HBOT) delivers 100% oxygen at atmospheric pressures greater than 1 ATA (atmosphere absolute), typically between 1.5 and 3.0 ATA. This simple physical principle — Henry's Law dictates that dissolved gas concentration in a liquid is proportional to the partial pressure of that gas above it — has profound therapeutic implications that are increasingly recognised in regenerative medicine, wound care, neurology, and longevity medicine.
The Physiology of HBOT: How It Works
Under normal atmospheric conditions, approximately 98% of oxygen in the blood is bound to haemoglobin, with only 2% dissolved in plasma. At 2.0–2.4 ATA with 100% oxygen, plasma-dissolved oxygen increases by up to 1,200%, allowing oxygen delivery to hypoxic tissues regardless of haemoglobin status.
This hyperoxic environment triggers multiple downstream effects:
- Angiogenesis: Hyperbaric oxygen stimulates VEGF (vascular endothelial growth factor) production, promoting new blood vessel formation in ischaemic tissues
- Stem cell mobilisation: HBOT increases circulating CD34+ stem cells by up to 800%, as demonstrated in the seminal Thom et al. studies
- Anti-inflammatory effects: Suppresses NF-κB signalling, reducing pro-inflammatory cytokine production
- Antimicrobial activity: Inhibits anaerobic organisms; potentiates antibiotic activity in infected tissues
- Collagen synthesis: Stimulates fibroblast proliferation and collagen deposition, critical for wound healing
- Telomere lengthening: Groundbreaking 2020 research by Hachmo et al. (Aging journal) demonstrated significant telomere lengthening and senescent cell clearance after 60 HBOT sessions
Established Clinical Indications
Regulatory bodies including the Undersea and Hyperbaric Medical Society (UHMS) and the European Committee for Hyperbaric Medicine (ECHM) have approved HBOT for the following conditions:
- Diabetic foot wounds and non-healing wounds
- Carbon monoxide poisoning
- Decompression sickness and arterial gas embolism
- Necrotising soft tissue infections (gas gangrene)
- Radiation-induced tissue damage (osteoradionecrosis, radiation cystitis)
- Crush injuries and compartment syndrome
- Idiopathic sudden sensorineural hearing loss
- Central retinal artery occlusion
- Refractory osteomyelitis
Emerging and Off-Label Applications
Beyond established indications, a robust and rapidly growing body of clinical evidence supports HBOT for several emerging applications:
Traumatic Brain Injury (TBI) and PTSD
Multiple randomised controlled trials, including the landmark Israeli military studies, demonstrate significant improvements in cognitive function, quality of life, and PTSD symptoms following HBOT in TBI patients. The proposed mechanism involves reverting metabolic dysfunction in the penumbral zone — tissue that is alive but non-functional due to chronic hypoxia.
Post-COVID Syndrome (Long COVID)
Emerging data from Israeli, UK, and US cohort studies show HBOT significantly improves cognitive function, fatigue, and exercise tolerance in Long COVID patients. The therapy appears to address the mitochondrial dysfunction and microclot pathology hypothesised to underlie Long COVID symptoms.
Stroke Rehabilitation
HBOT administered in the chronic phase post-stroke — previously considered beyond the therapeutic window — shows clinically meaningful neurological recovery in patients years after their event. The mechanism involves reactivation of dormant neurons in the peri-infarct zone.
Longevity and Anti-Aging
The Hachmo et al. (2020) protocol — 60 sessions of 90 minutes at 2.0 ATA, with air breaks — produced an average 38% increase in telomere length and 37% reduction in senescent cell burden in healthy aging adults. These findings, subsequently replicated in modified protocols, position HBOT as one of the most impactful longevity interventions currently available.
Autism Spectrum Disorder
A growing number of families and clinicians report meaningful improvements in language, social interaction, and behaviour following HBOT courses in children with ASD. The proposed mechanism involves reducing neuroinflammation and improving cerebral perfusion in under-active brain regions.
Clinical Protocols: What the Evidence Supports
Protocol parameters significantly influence outcomes. Key variables include:
- Pressure: 1.5–2.4 ATA is the evidence-based range for most indications. Higher is not always better — excessive pressure increases oxygen toxicity risk
- Duration: 60–90 minutes per session (excluding compression/decompression time)
- Frequency: Daily sessions (Monday–Friday) are standard for acute indications; 2–3x/week for chronic and longevity protocols
- Number of sessions: 20 sessions is the minimum meaningful course; 40–60 sessions for neurological and longevity applications
- Air breaks: 5-minute air breathing breaks every 20–30 minutes at higher pressures reduce oxygen toxicity risk
Safety Considerations and Contraindications
HBOT has an excellent safety profile when protocols are followed correctly. Key contraindications include:
- Untreated pneumothorax (absolute contraindication)
- Concurrent bleomycin or doxorubicin therapy
- Uncontrolled claustrophobia
- Eustachian tube dysfunction that cannot be managed with equalization techniques
- Active upper respiratory infection (relative contraindication)
The most common adverse effects are middle ear barotrauma (earache from pressure equalisation difficulty) and, rarely at higher pressures, oxygen toxicity seizures (incidence approximately 1 in 10,000 sessions).
HBOT at RegenX 2026
HBOT is a central topic at the RegenX Longevity Summit 2026. Dr. D. Sasikumar, HBOT Specialist and Ophthalmologist from India, will present the latest clinical evidence alongside practical protocols for integrating HBOT into regenerative medicine practices. The Mauritius edition (July 11–12, 2026) offers 8 CPD points from the Medical Council of Mauritius.
Conclusion
HBOT has graduated from a niche wound-care therapy to a mainstream regenerative medicine modality with compelling evidence across neurology, longevity, and complex wound management. Clinicians who understand its mechanisms, indications, and protocols are positioned to offer their patients one of the most versatile and well-evidenced therapies in the regenerative medicine toolkit.